Skip to content
TrialScanner

NCT04064346

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Phase 3TerminatedCNTACollaborator

Registry record

Lead sponsor
Palladio Biosciences
Conditions
Autosomal Dominant Polycystic Kidney; ADPKD
Primary completion
Aug 3, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04064346 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04064346: Efficacy and Safety of... | TrialScanner